BPC-157 vs GHK-Cu vs TB-500

Overview

BPC-157, GHK-Cu, and TB-500 are three peptides commonly marketed for tissue repair and recovery. All three lack FDA approval and have limited human clinical trial data. This comparison examines their proposed mechanisms, evidence quality, and key differences.

Important: None of these peptides is approved by regulatory agencies for clinical use. Evidence is primarily from preclinical studies.

Key Facts

Aspect	BPC-157	GHK-Cu	TB-500
Full Name	Body Protection Compound-157	Glycyl-L-Histidyl-L-Lysine:Copper	Thymosin Beta-4 Fragment
Structure	15 amino acids	3 amino acids + copper	43 amino acids (fragment of Tβ4)
Origin	Gastric juice protein	Naturally occurring tripeptide	Thymosin beta-4 derivative
FDA Status	Not approved	Not approved	Not approved
Primary Focus	GI, tendon, systemic	Skin, wound healing	Wound healing, mobility

Structure Comparison

Aspect	BPC-157	GHK-Cu	TB-500
Sequence Length	15 amino acids	3 amino acids	43 amino acids
Metal Component	None	Copper ion	None
Molecular Weight	~1,419 Da	~403 Da	~4,963 Da
Natural Occurrence	Derived from gastric protein	Found in plasma, saliva	Fragment of Tβ4

Mechanism Comparison

Aspect	BPC-157	GHK-Cu	TB-500
Primary Pathway	VEGF, NO system	Copper delivery, gene modulation	Actin sequestration
Secondary Effects	Growth factors	Collagen synthesis	Cell migration
Target Tissues	GI, tendon, muscle	Skin, connective tissue	Multiple tissues

BPC-157 Proposed Mechanisms

• Upregulation of VEGF and growth factors
• Modulation of nitric oxide system
• Effects on dopaminergic pathways
• Cytoprotective properties (GI)
• Angiogenesis promotion

GHK-Cu Proposed Mechanisms

• Copper delivery to tissues
• Collagen and elastin synthesis
• Anti-inflammatory gene expression
• Antioxidant effects
• Wound healing acceleration
• Skin remodeling

TB-500 Proposed Mechanisms

• G-actin sequestration
• Cell migration promotion
• Anti-inflammatory effects
• Angiogenesis
• Hair follicle stem cell migration

Evidence Quality Comparison

Factor	BPC-157	GHK-Cu	TB-500
Human RCTs	1-2 (limited)	Few (mostly cosmetic)	0
Animal Studies	Numerous	Numerous	Some
Research Groups	Primarily one (Croatia)	Multiple	Limited
Independent Replication	Limited	Better	Limited
Overall Evidence	Low	Low-Moderate	Very Low

BPC-157 Evidence

Source	Notes
Primary Research	Dr. Sikiric group (Zagreb, Croatia)
Study Types	Mostly rodent models
Conditions Studied	GI ulcers, tendons, muscles, inflammation
Limitations	Single research group, limited replication

GHK-Cu Evidence

Source	Notes
Primary Research	Multiple groups (cosmetic industry funded)
Study Types	In vitro, animal, limited human (topical)
Conditions Studied	Wound healing, skin aging
Limitations	Most human data is topical cosmetic use

TB-500 Evidence

Source	Notes
Primary Research	Based on thymosin beta-4 research
Study Types	Mostly extrapolated from Tβ4 data
Conditions Studied	Wound healing, cardiac
Limitations	TB-500 specifically is understudied

Preclinical Findings

BPC-157 (Animal Models)

Tissue	Claimed Effect
GI Tract	Ulcer healing, protection
Tendons	Accelerated healing
Muscles	Repair enhancement
Nerves	Possible regeneration

GHK-Cu (Various Models)

Area	Claimed Effect
Skin	Wound healing, anti-aging
Collagen	Increased synthesis
Inflammation	Reduction
Gene Expression	Multiple wound-healing genes

TB-500 (Extrapolated from Tβ4)

Tissue	Claimed Effect
Cardiac	Post-injury repair
Skin	Wound healing
Hair	Follicle activation
Muscle	Repair and flexibility

Administration Routes

Aspect	BPC-157	GHK-Cu	TB-500
Injection	SC, IM	SC (less common)	SC, IM
Oral	Claimed systemic (capsule)	Not typical	No
Topical	Claimed local	Yes (cosmetics)	No
Stability	Stable	Stable	Requires reconstitution

Route Considerations

Factor	BPC-157	GHK-Cu	TB-500
Oral Bioavailability	Claimed but unclear	Poor	Not established
Local Application	Studied	Established (topical)	Not typical
Systemic Effects	Claimed	Limited evidence	Proposed

Side Effect Profiles (Limited Data)

BPC-157 Reported Effects

Effect	Notes
Nausea	Occasional reports
Dizziness	Rare reports
Injection site	Typical for peptides
Unknown long-term	No safety data

GHK-Cu Reported Effects

Effect	Notes
Skin irritation	Possible (topical)
Injection site	If injected
Generally mild	When used topically

TB-500 Reported Effects

Effect	Notes
Fatigue	Occasional reports
Head rush	Some reports
Injection site	Typical for peptides
Unknown long-term	No safety data

Regulatory Status

Aspect	BPC-157	GHK-Cu	TB-500
FDA Status	Not approved	Not approved (cosmetic use OK)	Not approved
WADA Status	Prohibited	Not listed	Prohibited
Clinical Trials	None registered (US)	Limited	Tβ4 has some
Active Development	No pharma program	Cosmetic development	RegeneRx (Tβ4)

Comparison by Use Case

Musculoskeletal Recovery

Factor	BPC-157	GHK-Cu	TB-500
Tendon Claims	Strong focus	Limited	Some claims
Muscle Claims	Yes	Limited	Yes
Joint Claims	Some	Limited	Some
Evidence	Preclinical	Minimal	Extrapolated

Wound Healing

Factor	BPC-157	GHK-Cu	TB-500
Skin Wounds	Some claims	Primary focus	Some claims
Internal	GI focus	Not applicable	Some claims
Evidence	Preclinical	Better (topical)	Extrapolated

Anti-Aging

Factor	BPC-157	GHK-Cu	TB-500
Skin	Not primary	Yes	Limited
Systemic	Claimed	Limited	Limited
Evidence	Very limited	Some cosmetic	Very limited

Quality and Sourcing Concerns

All three peptides face similar challenges:

Issue	Impact
Unregulated sources	Unknown purity
No quality standards	Variable products
Contamination risk	Potential harm
Degradation	May be inactive
Mislabeling	Wrong product possible

Summary

Factor	BPC-157	GHK-Cu	TB-500
Evidence Level	Low	Moderate	Very Low
Primary Focus	GI, tendons	Skin, wounds	General repair
Research Source	Single group	Multiple	Extrapolated
Topical Use	Limited	Established	No
Injectable	Common	Less common	Common
FDA Approved	No	No	No
WADA Prohibited	Yes	No	Yes

Key Takeaways

1. None are approved: All three lack FDA approval for any indication
2. Evidence is limited: Primarily preclinical data, minimal human trials
3. Different mechanisms: Each works through distinct pathways
4. GHK-Cu has cosmetic use: Most established for topical skin application
5. BPC-157 research concerns: Primarily from single research group
6. TB-500 is least studied: Most claims extrapolated from thymosin beta-4
7. Quality concerns: Unregulated sources have unknown purity
8. Two are banned in sport: BPC-157 and TB-500 on WADA prohibited list
9. Not interchangeable: Different mechanisms for different proposed uses

---

This comparison is for educational purposes only. None of these peptides is approved by regulatory agencies. Products sold as research chemicals have uncertain quality and safety.